At the Global Business Summit 2025 in Hyderabad, Suven Pharmaceuticals' VP, Deepak Khurana, joined a panel discussion where he advocated for easing US patent laws to facilitate quicker market entry for Indian generics. This endorsement of deregulation and reduced oversight aligns with corporate strategies that may undermine public regulatory checks and contribute to broader authoritarian practices.

Suven Pharmaceuticals Ltd has published a comprehensive set of Business Responsibility and Sustainability Reporting policies. The document details anti-corruption measures, supplier code of conduct, labor rights, environmental standards, IT security, and responsible advocacy practices. These policies demonstrate the company’s commitment to ethical business practices and transparent governance, which are key to resisting authoritarian and fascist influences.

The Indian Cabinet approved a foreign direct investment of up to Rs.9589 crore in Suven Pharmaceuticals Ltd., potentially raising foreign ownership to 90.1%. While the move is touted to enhance operational capacity, job creation, and global best practices, anti-fascist critics view the increased foreign control as a structural shift that may undermine national sovereignty and democratic oversight in a critical healthcare sector.